{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:09:19Z","timestamp":1791036559051,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Henan Province of China","doi-asserted-by":"crossref","award":["092300410107"],"award-info":[{"award-number":["092300410107"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ejphar.2012.02.030","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T18:21:21Z","timestamp":1330107681000},"page":"10-15","source":"Crossref","is-referenced-by-count":59,"title":["In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates"],"prefix":"10.1016","volume":"683","author":[{"given":"Yu-Bing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Tao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Duan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2012.02.030_bb0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group","volume":"27","author":"Allen","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2012.02.030_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/095632020101200506","article-title":"Anti-HIV-1 activity and structure\u2013activity relationship of cepharanoline derivatives in chronically infected cells","volume":"12","author":"Baba","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir","volume":"41","author":"Brunelle","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2012.02.030_bb0020","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/AAC.01440-06","article-title":"In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants","volume":"51","author":"Brunelle","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0025","first-page":"39","article-title":"Traditional Chinese medicine and related active compounds against hepatitis B virus infection","volume":"4","author":"Cui","year":"2010","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.ejphar.2012.02.030_bb0030","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.77.21.11833-11841.2003","article-title":"The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro","volume":"77","author":"Delaney","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1053\/gast.2001.22454","article-title":"Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection","volume":"120","author":"Doo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2012.02.030_bb0040","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/jmv.20984","article-title":"Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences","volume":"79","author":"Enomoto","year":"2007","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0045","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/JVI.69.9.5437-5444.1995","article-title":"A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients","volume":"69","author":"G\u00fcnther","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2010.02.049","article-title":"Effect of Corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglias","volume":"635","author":"Guo","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0055","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"Hongthanakorn","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2012.02.030_bb0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1128\/AAC.50.3.955-961.2006","article-title":"In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2\u2032,3\u2032-dideoxy-3\u2032-fluoroguanosine","volume":"50","author":"Jacquard","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/135965350400900311","article-title":"In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir","volume":"9","author":"Lada","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0070","first-page":"107","article-title":"Study on the inhibitory effect of cepharanthine on herpes simplex type-1 virus (HSV-1) in vitro","volume":"27","author":"Liu","year":"2004","journal-title":"J. Chin. Med. Mater."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350901400504","article-title":"Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients","volume":"14","author":"Pollicino","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1734-1140(11)70500-X","article-title":"Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions","volume":"63","author":"Rogosnitzky","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jmv.20546","article-title":"Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants","volume":"78","author":"Suzuki","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jmv.10205","article-title":"Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus","volume":"68","author":"Wakil","year":"2002","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0100","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1128\/AAC.01764-09","article-title":"Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.antiviral.2011.01.005","article-title":"Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance","volume":"89","author":"Wang","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2893.2005.00578.x","article-title":"Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients","volume":"12","author":"Westland","year":"2005","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2003.07.003","article-title":"In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector","volume":"61","author":"Yang","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2010.06545.x","article-title":"Treatment of chronic hepatitis B: evolution over two decades","volume":"26","author":"Yuen","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1473-3099(09)70056-8","article-title":"Prevention and management of drug resistance for antihepatitis B treatment","volume":"9","author":"Yuen","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2012.02.030_bb0130","first-page":"493","article-title":"Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro","volume":"118","author":"Zhang","year":"2005","journal-title":"Chin. Med. J. (Engl)."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912001665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912001665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T17:08:25Z","timestamp":1687280905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299912001665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":26,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0014299912001665"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.02.030","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}